Stockreport

Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting [Yahoo! Finance]

Prelude Therapeutics Incorporated  (PRLD) 
PDF Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved [Read more]